查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587661

2030年甲狀腺疾病治療市場預測：依疾病類型、治療類型、給藥途徑、藥物類型、通路和地區進行全球分析

Thyroid Gland Disorders Treatment Market Forecasts to 2030 - Global Analysis By Type of Disorder, Treatment Type, Route of Administration, Drug Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球甲狀腺疾病治療市場規模為 25 億美元，預計 2030 年將達到 36.9 億美元，預測期內複合年成長率為 6.7%。

甲狀腺疾病治療是指旨在控制影響甲狀腺的疾病的醫療干預措施。常見的甲狀腺疾病包括甲狀腺機能低下症（甲狀腺機能低下症）、甲狀腺功能亢進（hyperthymosis）、甲狀腺結節、甲狀腺癌等。治療方法因疾病而異，包括荷爾蒙補充療法、抗甲狀腺藥物、放射性碘和手術。

根據加拿大癌症協會的2022年報告，2022年將有近6,700名加拿大人被診斷出罹患甲狀腺癌。

甲狀腺疾病增加

甲狀腺疾病盛行率的上升和人們對甲狀腺健康意識的提高，加上診斷技術的進步，將導致早期發現和早期治療。患者數量的增加推動了對有效治療的需求，包括藥物治療、放射性碘治療和手術干預。此外，肥胖和自體免疫疾病等危險因子的普遍存在進一步加劇了市場的成長。因此，製藥公司正在增加研發投資，以提供創新的治療方法。

昂貴的治療費用

治療甲狀腺疾病的高成本限制了患者獲得必要的治療，這嚴重阻礙了市場的成長。許多患者可能因經濟困難而放棄或推遲治療，導致健康狀況惡化。此外，保險範圍有時不足，進一步加劇了財務問題。這種情況阻礙了製藥公司投資新治療方法，並減少了市場的創新和競爭。結果，治療的整體有效性下降，影響患者的治療結果，增加醫療保健系統的負擔，並阻礙市場成長。

夥伴關係與聯合研究

甲狀腺疾病治療市場的聯盟與合作將加強研究和開發，並促進製藥公司、醫療保健提供者和研究機構之間的專業知識和資源共用。這些合作加速了藥物開發的創新和先進治療方法的引入，以改善患者的治療效果。協作努力還可以帶來更有效的行銷策略，提高治療方法的認知和可及性。此外，夥伴關係關係加速了臨床試驗，縮短了新治療方法的上市時間，協助獲得監管部門的核准，並最終推動市場成長。

激烈的競爭

甲狀腺疾病治療市場的激烈競爭可能會壓低價格並降低製造商的利潤率，從而阻礙成長。公司可能會在行銷和促銷方面投入大量資金以獲得市場佔有率，從而導致營運成本增加。此外，專注於將自己與競爭對手區分開來可能會耗盡研發資源，並阻礙治療方案的創新。由於公司將短期利潤置於長期進步之上，患者獲得尖端治療方法的機會可能有限，最終影響整體市場成長和患者治療結果。

COVID-19 的影響

COVID-19 大流行擾亂了醫療保健服務、延遲了診斷並限制了常規護理的獲得，從而影響了甲狀腺疾病的治療。甲狀腺疾病患者，特別是那些需要定期監測或手術的患者，由於醫療系統負擔過重而面臨治療延誤。遠端醫療已經成為一種解決方案，可以進行遠距諮詢和管理。此外，COVID-19 對免疫系統的影響與甲狀腺發炎（甲狀腺炎）之間的關聯引起了人們對病毒可能引起的甲狀腺功能障礙的擔憂，並影響了大流行期間和大流行後的治療方法。

預計藥物治療領域在預測期內將是最大的。

在預測期內，由於管理常見甲狀腺疾病的非侵入性解決方案，藥物治療領域預計將創下最大的市場佔有率。甲狀腺機能低下症通常用於治療甲狀腺功能減退症，以替代缺失的激素，而甲硫咪唑和丙硫氧嘧啶等抗甲狀腺藥物則透過抑制過量的激素產生來治療甲狀腺功能亢進。這些藥物可以提供長期的疾病控制，並且通常可以延遲或避免手術或放射性碘治療的需要。

在預測期內，注射劑領域的複合年成長率最高。

在預測期內，注射劑領域預計將以最高複合年成長率成長。這是因為其有效且有針對性的治療選擇，特別是對於患有嚴重甲狀腺功能障礙的患者。甲狀腺激素注射和生技藥品等注射治療可以快速緩解甲狀腺機能低下症和甲狀腺相關緊急情況等病症。由於可以施用精確的劑量，因此可以比內服藥物更可靠地控制甲狀腺激素水平。注射劑的日益普及、藥物配方的進步以及甲狀腺疾病盛行率的增加都促進了這一領域的成長。

比最大的地區

在估計期間，由於人們對甲狀腺疾病的認知不斷提高以及醫療技術的進步，預計亞太地區將佔據最大的市場佔有率。主要治療方法包括荷爾蒙替代療法、抗甲狀腺藥物和手術介入。由於患者人數的增加和醫療基礎設施的改善，印度和中國等國家正在經歷顯著的成長。此外，政府促進甲狀腺健康的措施和擴大採用遠端醫療正在進一步推動市場成長。

複合年成長率最高的地區：

由於甲狀腺相關疾病（包括甲狀腺機能低下症和甲狀腺功能亢進症）的盛行率不斷上升，預計北美地區在預測期內將實現最高的複合年成長率。診斷技術的進步和標靶治療的不斷採用正在促進市場擴張。此外，醫療保健專業人員和患者對甲狀腺疾病的認知不斷提高，推動了對有效治療的需求，包括荷爾蒙補充療法和手術選擇。此外，主要市場參與者的存在和對創新治療方法的不斷探索預計將進一步增強該地區的市場活力。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球甲狀腺疾病治療市場：依疾病類型

  • 甲狀腺機能低下症
  • 甲狀腺功能亢進症
  • 甲狀腺腫
  • 甲狀腺癌
  • 橋本氏症
  • 格雷夫茲病
  • 甲狀腺結節
  • 其他疾病類型

第6章全球甲狀腺疾病治療市場：依治療類型

  • 藥品
    • 荷爾蒙補充療法
    • 抗甲狀腺藥物
    • 放射性碘治療
  • 外科手術
    • 甲狀腺切除術
    • 切除術
  • 射頻消融術
  • 其他治療類型
    • 食品補充品
    • 草藥療法

第7章全球甲狀腺疾病治療市場：依給藥途徑

  • 口服
  • 注射
  • 外用
  • 其他給藥途徑

第8章全球甲狀腺疾病治療市場：依藥物類型

  • 左旋甲狀腺素
  • 三碘甲狀腺胺酸
  • 丙硫氧嘧啶
  • 咪唑類化合物
  • 其他藥物類型

第9章全球甲狀腺疾病治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 診所
  • 其他分銷管道

第10章全球甲狀腺疾病治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 公司概況

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • ThyroSafe, LLC
  • Hormone Health Network
  • Zydus Cadila
  • Mylan NV
  • Hikma Pharmaceuticals PLC
  • Endo International PLC
  • Genzyme Corporatio
  • Roche Holding AG
Product Code: SMRC27646

According to Stratistics MRC, the Global Thyroid Gland Disorders Treatment Market is accounted for $2.50 billion in 2024 and is expected to reach $3.69 billion by 2030 growing at a CAGR of 6.7% during the forecast period. Thyroid gland disorders treatment refers to medical interventions aimed at managing conditions that affect the thyroid, a small gland in the neck responsible for regulating metabolism. Common thyroid disorders include hypothyroidism (underactive thyroid), hyperthyroidism (overactive thyroid), thyroid nodules, and thyroid cancer. Treatment options vary based on the disorder and may include hormone replacement therapy, anti-thyroid medications, radioactive iodine, or surgery.

According to the Canadian Cancer Society 2022 report, close to 6,700 Canadians were diagnosed with thyroid cancer in the year 2022.

Market Dynamics:

Driver:

Rising incidence of thyroid disorders

The rising incidence of thyroid disorders and increasing awareness of thyroid health, coupled with advancements in diagnostic technologies, leads to earlier detection and treatment. This growing patient population drives demand for effective therapies, including medications, radioactive iodine therapy, and surgical interventions. Additionally, the prevalence of risk factors such as obesity and autoimmune diseases further escalates the market's growth. Consequently, pharmaceutical companies are increasingly investing in research and development to offer innovative treatment options.

Restraint:

High cost of treatments

The high cost of treatments for thyroid gland disorders significantly hinders market growth by limiting patient access to necessary therapies. Many individuals may forgo or delay treatment due to financial constraints, leading to worsening health conditions. Additionally, insurance coverage can be inadequate, further exacerbating affordability issues. This situation discourages pharmaceutical companies from investing in new therapies, reducing innovation and competition in the market. Consequently, the overall treatment landscape becomes less effective, impacting patient outcomes and increasing the burden on healthcare systems, thus hindering the growth of the market.

Opportunity:

Partnerships and collaborations

Partnerships and collaborations in the thyroid gland disorders treatment market enhance research and development, facilitating the sharing of expertise and resources among pharmaceutical companies, healthcare providers, and research institutions. These alliances foster innovation in drug development and the introduction of advanced treatment modalities, improving patient outcomes. Collaborative efforts can also lead to more effective marketing strategies, increasing awareness and accessibility of therapies. Furthermore, partnerships can accelerate clinical trials, shorten time-to-market for new treatments, and help in obtaining regulatory approvals, ultimately propelling market growth.

Threat:

Intense competition

Intense competition in the thyroid gland disorders treatment market can hinder growth by driving down prices, which may reduce profit margins for manufacturers. Companies may invest heavily in marketing and promotions to gain market share, leading to increased operational costs. Additionally, the focus on competitive differentiation can divert resources from research and development, stalling innovation in treatment options. As companies prioritize short-term gains over long-term advancements, patients may face limited access to cutting-edge therapies, ultimately impacting overall market growth and patient outcomes.

Covid-19 Impact

The COVID-19 pandemic impacted thyroid gland disorders treatment by disrupting healthcare services, delaying diagnoses, and limiting access to routine care. Patients with thyroid disorders, especially those requiring regular monitoring or surgery, face postponements due to overwhelmed healthcare systems. Telemedicine emerged as a solution, enabling remote consultations and management. Additionally, COVID-19's effects on the immune system and its association with thyroid inflammation (thyroiditis) increased concerns about potential virus-induced thyroid dysfunction, influencing treatment approaches during and after the pandemic.

The medications segment is expected to be the largest during the forecast period

During the forecast period, the medications segment is anticipated to register the largest market share, due to non-invasive solutions for managing common thyroid conditions. For hypothyroidism, levothyroxine is widely prescribed to replace deficient hormones, while antithyroid drugs like methimazole and propylthiouracil treat hyperthyroidism by reducing excessive hormone production. These medications provide long-term disease management, often delaying or preventing the need for surgery or radioactive iodine therapy.

The injectable segment is expected to have the highest CAGR during the forecast period

During the projection period, the injectable segment is expected to grow at the highest CAGR, due to efficient and targeted treatment options, especially for patients with severe thyroid dysfunction. Injectable treatments, such as thyroid hormone injections or biologics, provide rapid relief in conditions like hypothyroidism or thyroid-related emergencies. Their effectiveness in delivering precise doses ensures better control of thyroid hormone levels compared to oral medications. The growing adoption of injectables, advancements in drug formulations, and the increasing prevalence of thyroid disorders contribute to the segment's growth.

Region with largest share:

During the estimation period, the Asia Pacific region is expected to capture the largest market share due to raised awareness of thyroid diseases and advancements in medical technology. Key therapies include hormone replacement treatments, antithyroid medications, and surgical interventions. Countries like India and China are witnessing significant growth driven by a growing patient population and enhanced healthcare infrastructure. Moreover, government initiatives promoting thyroid health and the rising adoption of telemedicine are further propelling market growth.

Region with highest CAGR:

The North America region is projected to achieve the highest CAGR during the forecast period, due to the rising prevalence of thyroid-related conditions, including hypothyroidism and hyperthyroidism. Advances in diagnostic technologies and the increasing adoption of targeted therapies contribute to market expansion. Additionally, the growing awareness of thyroid disorders among healthcare professionals and patients drives demand for effective treatments, including hormone replacement therapies and surgical options. Moreover, the presence of key market players and ongoing research into innovative therapies are expected to further enhance market dynamics in the region.

Key players in the market

Some of the key players profiled in the Thyroid Gland Disorders Treatment Market include Abbott Laboratories, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Boehringer Ingelheim GmbH, Amgen Inc., Takeda Pharmaceutical Company Limited, ThyroSafe, LLC, Hormone Health Network, Zydus Cadila, Mylan N.V., Hikma Pharmaceuticals PLC, Endo International PLC, Genzyme Corporation and Roche Holding AG.

Key Developments:

In September 2024, Abbott announced collaboration with the DoD to develop and distribute a rapid COVID-19 test that provides results in under 30 minutes, aiming to enhance testing capabilities for military personnel.

In August 2024, Abbott acquired Walk Vascular, a company specializing in advanced vascular access solutions, enhancing its product portfolio in medical devices for vascular access.

In April 2024, Abbott formed a joint venture with Axiom Health to create digital health solutions that integrate diagnostics with data analytics to improve patient outcomes in chronic disease management.

Type of Disorders Covered:

  • Hypothyroidism
  • Hyperthyroidism
  • Goiter
  • Thyroid Cancer
  • Hashimoto's Thyroiditis
  • Graves' Disease
  • Thyroid Nodules
  • Other Type of Disorders

Treatment Types Covered:

  • Medications
  • Surgery
  • Radiofrequency Ablation
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Injectable
  • Topical
  • Other Route of Administrations

Drug Types Covered:

  • Levothyroxine
  • Liothyronine
  • Propylthiouracil
  • Imidazole-Based Compounds
  • Other Drug Types

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thyroid Gland Disorders Treatment Market, By Type of Disorder

  • 5.1 Introduction
  • 5.2 Hypothyroidism
  • 5.3 Hyperthyroidism
  • 5.4 Goiter
  • 5.5 Thyroid Cancer
  • 5.6 Hashimoto's Thyroiditis
  • 5.7 Graves' Disease
  • 5.8 Thyroid Nodules
  • 5.9 Other Type of Disorders

6 Global Thyroid Gland Disorders Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Medications
    • 6.2.1 Hormone Replacement Therapy
    • 6.2.2 Antithyroid Drugs
    • 6.2.3 Radioactive Iodine Therapy
  • 6.3 Surgery
    • 6.3.1 Thyroidectomy
    • 6.3.2 Lobectomy
  • 6.4 Radiofrequency Ablation
  • 6.5 Other Treatment Types
    • 6.5.1 Nutritional Supplements
    • 6.5.2 Herbal Remedies

7 Global Thyroid Gland Disorders Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Topical
  • 7.5 Other Route of Administrations

8 Global Thyroid Gland Disorders Treatment Market, By Drug Type

  • 8.1 Introduction
  • 8.2 Levothyroxine
  • 8.3 Liothyronine
  • 8.4 Propylthiouracil
  • 8.5 Imidazole-Based Compounds
  • 8.6 Other Drug Types

9 Global Thyroid Gland Disorders Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Clinics
  • 8.6 Other Distribution Channels

10 Global Thyroid Gland Disorders Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AstraZeneca PLC
  • 12.3 Bristol-Myers Squibb Company
  • 12.4 Eli Lilly and Company
  • 12.5 GlaxoSmithKline PLC
  • 12.6 Merck & Co., Inc.
  • 12.7 Novartis AG
  • 12.8 Pfizer Inc.
  • 12.9 Sanofi S.A.
  • 12.10 Boehringer Ingelheim GmbH
  • 12.11 Amgen Inc.
  • 12.12 Takeda Pharmaceutical Company Limited
  • 12.13 ThyroSafe, LLC
  • 12.14 Hormone Health Network
  • 12.15 Zydus Cadila
  • 12.16 Mylan N.V.
  • 12.17 Hikma Pharmaceuticals PLC
  • 12.18 Endo International PLC
  • 12.19 Genzyme Corporatio
  • 12.20 Roche Holding AG

List of Tables

  • Table 1 Global Thyroid Gland Disorders Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2022-2030) ($MN)
  • Table 3 Global Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2022-2030) ($MN)
  • Table 4 Global Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2022-2030) ($MN)
  • Table 5 Global Thyroid Gland Disorders Treatment Market Outlook, By Goiter (2022-2030) ($MN)
  • Table 6 Global Thyroid Gland Disorders Treatment Market Outlook, By Thyroid Cancer (2022-2030) ($MN)
  • Table 7 Global Thyroid Gland Disorders Treatment Market Outlook, By Hashimoto's Thyroiditis (2022-2030) ($MN)
  • Table 8 Global Thyroid Gland Disorders Treatment Market Outlook, By Graves' Disease (2022-2030) ($MN)
  • Table 9 Global Thyroid Gland Disorders Treatment Market Outlook, By Thyroid Nodules (2022-2030) ($MN)
  • Table 10 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Type of Disorders (2022-2030) ($MN)
  • Table 11 Global Thyroid Gland Disorders Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 12 Global Thyroid Gland Disorders Treatment Market Outlook, By Medications (2022-2030) ($MN)
  • Table 13 Global Thyroid Gland Disorders Treatment Market Outlook, By Hormone Replacement Therapy (2022-2030) ($MN)
  • Table 14 Global Thyroid Gland Disorders Treatment Market Outlook, By Antithyroid Drugs (2022-2030) ($MN)
  • Table 15 Global Thyroid Gland Disorders Treatment Market Outlook, By Radioactive Iodine Therapy (2022-2030) ($MN)
  • Table 16 Global Thyroid Gland Disorders Treatment Market Outlook, By Surgery (2022-2030) ($MN)
  • Table 17 Global Thyroid Gland Disorders Treatment Market Outlook, By Thyroidectomy (2022-2030) ($MN)
  • Table 18 Global Thyroid Gland Disorders Treatment Market Outlook, By Lobectomy (2022-2030) ($MN)
  • Table 19 Global Thyroid Gland Disorders Treatment Market Outlook, By Radiofrequency Ablation (2022-2030) ($MN)
  • Table 20 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 21 Global Thyroid Gland Disorders Treatment Market Outlook, By Nutritional Supplements (2022-2030) ($MN)
  • Table 22 Global Thyroid Gland Disorders Treatment Market Outlook, By Herbal Remedies (2022-2030) ($MN)
  • Table 23 Global Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 24 Global Thyroid Gland Disorders Treatment Market Outlook, By Oral (2022-2030) ($MN)
  • Table 25 Global Thyroid Gland Disorders Treatment Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 26 Global Thyroid Gland Disorders Treatment Market Outlook, By Topical (2022-2030) ($MN)
  • Table 27 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Route of Administrations (2022-2030) ($MN)
  • Table 28 Global Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 29 Global Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2022-2030) ($MN)
  • Table 30 Global Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2022-2030) ($MN)
  • Table 31 Global Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2022-2030) ($MN)
  • Table 32 Global Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2022-2030) ($MN)
  • Table 33 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 34 Global Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 35 Global Thyroid Gland Disorders Treatment Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 36 Global Thyroid Gland Disorders Treatment Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 37 Global Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 38 Global Thyroid Gland Disorders Treatment Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 39 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.